TriangleNCT01775475 · OUTCOME
Progression-free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- proportion
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 24 months
What was measured
Proportion of participants who survived without disease progression at 2 years
Analysis population: Participants whose disease and survival status were known at 2 years
Groups in this outcome
Arm I (CHOP)
Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide: Given IV doxorubicin hydrochloride: Given IV vincristine sulfate: Given IV prednisone: Given PO laboratory biomarker analysis: Correlative studies
Arm II (Oral Chemotherapy)
Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. lomustine: Given PO etoposide: Given PO cyclophosphamide: Given PO procarbazine hydrochloride: Given PO laboratory biomarker analysis: Correlative studies
| Group | Source count |
|---|---|
| Arm I (CHOP) | 3 |
| Arm II (Oral Chemotherapy) | 3 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm I (CHOP) | 0 | Not reported | 0 | 0 | Not reported |
| Arm II (Oral Chemotherapy) | 0 | Not reported | 0 | 0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0
- upper Limit
- 0
- value
- 0
- group Id
- OG001
- lower Limit
- 0
- upper Limit
- 0
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- units
- Participants
- description
- Proportion of participants who survived without disease progression at 2 years
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. cyclophosphamide: Given IV doxorubicin hydrochloride: Given IV vincristine sulfate: Given IV prednisone: Given PO laboratory biomarker analysis: Correlative studies
- id
- OG000
- title
- Arm I (CHOP)
- description
- Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. lomustine: Given PO etoposide: Given PO cyclophosphamide: Given PO procarbazine hydrochloride: Given PO laboratory biomarker analysis: Correlative studies
- id
- OG001
- title
- Arm II (Oral Chemotherapy)
- param Type
- NUMBER
- population Description
- Participants whose disease and survival status were known at 2 years
- reporting Status
- POSTED
- time Frame
- Up to 24 months
- title
- Progression-free Survival
- type
- PRIMARY
- unit Of Measure
- proportion
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice